Olema shareholders elect directors, approve executive compensation, ratify auditor at 2026 annual meeting

Olema Pharmaceuticals, Inc.

Four Class III directors elected: Bohen (67.5M for), Garland (66.2M), Larson (50.4M), Rappaport (67.3M).
Advisory vote on executive compensation approved: 68.0M for, 654K against, 15.9K abstain.
Ernst & Young ratified as independent auditor for FY2026: 75.8M for, 272K against, 52.5K abstain.
Broker non-votes of 7.5M on director and compensation proposals; none on auditor ratification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.